What are Bispecific checkpoint inhibitor drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bispecific checkpoint inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting PD-1 and TIM-3). 0 are currently marketed, with 9 more in clinical development.

Bispecific checkpoint inhibitor

0 marketed 8 in Phase 3 1 in Phase 2

This page covers all Bispecific checkpoint inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1 and TIM-3, PD-L1 and CEACAM1 (TIM-3 ligand), PD-1 and CTLA-4.

Targets

PD-1 and TIM-3 · PD-L1 and CEACAM1 (TIM-3 ligand) · PD-1 and CTLA-4

Phase 3 pipeline (8)

AK104(IV) · Akeso · Oncology
AK104 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.
IBI310 · Innovent Biologics (Suzhou) Co. Ltd. · Oncology
IBI310 is a bispecific antibody that simultaneously engages PD-1 on T cells and TIM-3 on tumor-infiltrating lymphocytes to enhance anti-tumor immune responses.
BAT2306 · Bio-Thera Solutions · Oncology
BAT2306 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
BAT2506 injection · Bio-Thera Solutions · Oncology
BAT2506 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
BAT5906 injection · Bio-Thera Solutions · Oncology
BAT5906 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
FKB327 · Fujifilm Kyowa Kirin Biologics Co., Ltd. · Oncology
FKB327 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.
IBI363 · Innovent Biologics (Suzhou) Co. Ltd. · Oncology
IBI363 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.
AK102 · Akeso · Oncology
AK102 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.

Phase 2 pipeline (1)

AK112 high dose · Akeso · Oncology
AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.

Patent intelligence

bispecific checkpoint inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates